PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Clinical trials for PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outsmart Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—vismodegib and atezolizumab—in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combination is safe and can shrink tumor…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
Disease control Recruiting nowThis Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Ira Winer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug lorigerlimab takes on Platinum-Resistant ovarian cancer
Disease control Recruiting nowThis phase 2 trial is testing a drug called lorigerlimab in about 80 people with advanced ovarian or clear cell gynecologic cancers that have stopped responding to platinum chemotherapy. Lorigerlimab is a bispecific antibody designed to activate the immune system against tumors. …
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Supercharged immune cells take on tough ovarian cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with ovarian cancer that has returned or is resistant to standard platinum chemotherapy. The treatment uses a patient's own immune cells (T cells), which are trained in a lab to recognize and attack a protein called MUC1 fou…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for Platinum-Resistant ovarian cancer: PLX038 trial launches
Disease control Recruiting nowThis Phase II trial tests a drug called PLX038 in 43 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if it shrinks tumors a…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC